Clinical and oncological features of children and young adults with multiple endocrine neoplasia type 2A

Thyroid

Volumn 18, Issue 12, 2008, Pages 1261-1268

  Puñales, Márcia K C ^a   Da Rocha, Andreia Possatti ^a   Meotti, Camila ^a   Gross, Jorge L ^a   Maia, Ana Luiza ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; PROTEIN RET;

ADOLESCENT; ADULT; ARTICLE; CALCITONIN BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE COURSE; DISTANT METASTASIS; ECHOGRAPHY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HYPERPARATHYROIDISM; LYMPH NODE METASTASIS; MALE; PHEOCHROMOCYTOMA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA; THYROID NODULE; THYROIDECTOMY; TREATMENT OUTCOME;

ADOLESCENT; CALCITONIN; CARCINOMA, MEDULLARY; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PROTO-ONCOGENE PROTEINS C-RET; RECURRENCE; RISK; THYROID GLAND; THYROID NEOPLASMS; THYROID NODULE; THYROIDECTOMY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 57449107613     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2007.0414     Document Type: Article

References (35)

1. Ponder BA 1999 The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome. Cancer Res 59:1736s-1741s; discussion 1742s.
2. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HKP, Lips CJM, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjõld M, Komminoth P, Hendy GN, Gharib H, Thibodeau SN, Lacroix A, Frilling A 1996 The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276:1575-1579.
3. Mulligan LM, Marsh DJ, Robinson BG, Schuffeenecker I, Zedenius J, Lips CJM, Gagel RF, Takai SI, Noll WW, Fink M, Raue F, Lacroix A, Thibodeau SN, Frilling A, Ponder BAJ, Eng C 1995 Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 238:343-346.
4. Machens A, Gimm O, Hinze R, Hoppner W, Boehm BO, Dralle H 2001 Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J Clin Endocrinol Metab 86:1104-1109.
5. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA, Jr., Marx SJ 2001 Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658-5671.
6. Caron P, Attie T, David D, Amiel J, Brousset F, Roger P, Munnich A, Lyonnet S 1996 C618R mutation in exon 10 of the RET proto-oncogene in a kindred with multiple endocrine neoplasia type 2A and Hirschsprung's disease. J Clin Endocrinol Metab 81:2731-2733.
7. Eng C 1996 Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. N Engl J Med 335:943-951.
8. Nunziata V, Giannattasio R, Di Giovanni G, D'Armiento MR, Mancini M 1989 Hereditary localized pruritus in affected members of a kindred with multiple endocrine neoplasia type 2A (Sipple's syndrome). Clin Endocrinol (Oxf ) 30:57-63.
9. Gagel RF, Levy ML, Donovan DT, Alford BR, Wheeler T, Tschen JA 1989 Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis. Ann Intern Med 111:802-806.
10. Heshmati HM, Gharib H, van Heerden JA, Sizemore GW 1997 Advances and controversies in the diagnosis and management of medullary thyroid carcinoma. Am J Med 103:60-69.
11. Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD, Wahl RA, Lamesch P, Raue F, Conte-Devolx B, Dralle H 2003 Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349:1517-1525.
12. Gill JR, Reyes-Mugica M, Iyengar S, Kidd KK, Touloukian RJ, Smith C, Keller MS, Genel M 1996 Early presentation of metastatic medullary carcinoma in multiple endocrine neoplasia, type IIA: implications for therapy. J Pediatr 129:459-464.
13. Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, Sherman SI, Lee JE, Evans DB 2005 RET protooncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15:531-544.
14. Wells SA, Jr., Chi DD, Toshima K, Dehner LP, Coffin CM, Dowton SB, Ivanovich JL, DeBenedetti MK, Dilley WG, Moley JF, Norton AJ, Donis-Keller H 1994 Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 220:237-247; discussion 247-250.
15. Machens A, Ukkat J, Brauckhoff M, Gimm O, Dralle H 2005 Advances in the management of hereditary medullary thyroid cancer. J Intern Med 257:50-59.
16. Machens A, Holzhausen HJ, Thanh PN, Dralle H 2003 Malignant progression from C-cell hyperplasia to medullary thyroid carcinoma in 167 carriers of RET germline mutations. Surgery 134:425-431.
17. Dralle H, Gimm O, Simon D, Frank-Raue K, Gortz G, Niederle B, Wahl RA, Koch B, Walgenbach S, Hampel R, Ritter MM, Spelsberg F, Heiss A, Hinze R, Hoppner W 1998 Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg 22:744-750; discussion 750-751.
18. Learoyd DL, Gosnell J, Elston MS, Saurine TJ, Richardson AL, Delbridge LW, Aglen JV, Robinson BG 2005 Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations. Clin Endocrinol (Oxf ) 63:636-641.
19. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH 2000 Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88:1139-1148.
20. Cote GJ, Gagel RF 2003 Lessons learned from the management of a rare genetic cancer. N Engl J Med 349:1566-1568.
21. Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK, Wells SA, Jr. 2005 Prophylactic thyroidectomy inmultiple endocrine neoplasia type 2A. N Engl J Med 353:1105-1113.
22. Szinnai G, Meier C, Komminoth P, Zumsteg UW 2003 Review of multiple endocrine neoplasia type 2A in children: therapeutic results of early thyroidectomy and prognostic value of codon analysis. Pediatrics 111:E132-E139.
23. Frank-Raue K, Buhr H, Dralle H, Klar E, Senninger N, Weber T, Rondot S, Hoppner W, Raue F 2006 Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. Eur J Endocrinol 155:229-236.
24. Sanso GE, Domene HM, Garcia R, Pusiol E, de M, Roque M, Ring A, Perinetti H, Elsner B, Iorcansky S, Barontini M 2002 Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers. Cancer 94:323-330.
25. Ramos C, Ojeda D, Cohn D, Wohllk N 2005 Prophylactic thyroidectomy in children and young people with hereditary medullary thyroid carcinoma: a Chilean experience. Rev Med Chil 133:1029-1036.
26. Hansen HS, Torring H, Godballe C, Jager AC, Nielsen FC 2000 Is thyroidectomy necessary in RET mutations carriers of the familial medullary thyroid carcinoma syndrome? Cancer 89:863-867.
27. Punales MK, Graf H, Gross JL, Maia AL 2003 RET codon 634 mutations in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome. J Clin Endocrinol Metab 88:2644-2649.
28. O'Sullivan B, Shah J 2003 New TNM staging criteria for head and neck tumors. Semin Surg Oncol 21:30-42.
29. Piolat C, Dyon JF, Sturm N, Pinson S, Bost M, Jouk SP, Plantaz D, Chabre O 2006 Very early prophylactic thyroid surgery for infants with a mutation of the RET protooncogene at codon 634: evaluation of the implementation of international guidelines for MEN type 2 in a single centre. Clin Endocrinol (Oxf ) 65:118-124.
30. Machens A, Schneyer U, Holzhausen HJ, Dralle H 2005 Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 90:2029-2034.
31. Cohen MS, Moley JF 2003 Surgical treatment of medullary thyroid carcinoma. J Intern Med 253:616-626.
32. Moley JF, Debenedetti MK, Dilley WG, Tisell LE, Wells SA 1998 Surgical management of patients with persistent or recurrent medullary thyroid cancer. J Intern Med 243:521-526.
33. Hyer SL, Vini L, A'Hern R, Harmer C 2000 Medullary thyroid cancer: multivariate analysis of prognostic factors influencing survival. Eur J Surg Oncol 26:686-690.
34. Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, Schlumberger M, Bigorgne CJ, Dumontier P, Leclerc L 1998 Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'etude des tumeurs a calcitonine. Clin Endocrinol (Oxf ) 48:265-273.
35. Jackson MB, Guttenberg M, Hedrick H, Moshang T, Jr. 2005 Multiple endocrine neoplasia type 2A in a kindred with C634Y mutation. Pediatrics 116:e468-e471.